Table 1.
Characteristics of patients who underwent the capsule endoscopy.
| Total N = 23 |
Positive Findings n = 14 |
No Findings n = 9 |
p-Value | ||
|---|---|---|---|---|---|
| Median age, range (years) | 67 (31–83) | 68 (31–83) | 66 (42–79) | 0.83 | |
| Male, no (%) | 21 (91%) | 14 (100%) | 7 (78%) | 0.044 * | |
| BMI, kg/m2, range | 19.6 (16–30.4) | 21.6 (17.6–30.4) | 17.9 (16–28.2) | 0.10 | |
| ECOG PS, no (%) | 0 | 8 (35%) | 6 (43%) | 2 (22%) | 0.30 |
| 1 | 15 (65%) | 8 (57%) | 7 (78%) | ||
| Primary tumor, no (%) | 0.28 | ||||
| Renal cell carcinoma | 12 (52%) | 8 (57%) | 4 (44%) | ||
| Gastric cancer | 6 (26%) | 4 (29%) | 2 (22%) | ||
| Esophageal cancer | 2 (9%) | 0 | 2 (22%) | ||
| Malignant melanoma | 2 (9%) | 1 (7%) | 1 (11%) | ||
| MSI-H solid tumor | 1 (4%) | 1 (7%) | 0 | ||
| Immune checkpoint inhibitors, no (%) | 0.32 | ||||
| Nivolumab | 20 (87%) | 11 (79%) | 9 (100%) | ||
| Pembrolizumab | 2 (9%) | 2 (14%) | 0 | ||
| Nivolumab plus ipilimumab | 1 (4%) | 1 (7%) | 0 | ||
| Median Lichtiger score, range | 0 (0–3) | 0 (0–1) | 0 (0–3) | 0.38 | |
| NSAIDs usage, no (%) | 6 (26%) | 3 (21%) | 3 (33%) | 0.37 | |
| PPI usage, no (%) | 8 (35%) | 5 (36%) | 3 (33%) | 0.90 | |
| Baseline laboratory findings | |||||
| WBC, range (/μL) | 6400 (3500–13,700) | 7000 (3500–13,700) | 6200 (4200–7300) | 0.20 | |
| Hb, range (g/dL) | 12.4 (7.7–15.1) | 12.6 (7.7–15.1) | 12.2 (8.8–14.5) | 0.70 | |
| CRP, range (mg/dL) | 0.25 (0.01–2.8) | 0.16 (0.01–2.8) | 0.1 (0.01–1.55) | 0.42 | |
Abbreviations: BMI, body mass index; CRP, C-reactive protein; ECOG, European cooperative oncology group; Hb, hemoglobin; MSI-H, microsatellite instability-high; NSAIDs, nonsteroidal anti-inflammatory drugs; PPI, proton pump inhibitors; PS, performance status; WBC, white blood cell. One asterisk (*) indicates p value smaller than 0.05 (p < 0.05).